Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Peretinoin shows potential as first-line agent to prevent recurrence of HCC

Sep. 22, 2010

Phase III data presented on bisoprolol vs. carvedilol in elderly subjects with CHF

Sep. 22, 2010

Galapagos develops new phosphodiesterase 1A inhibitors for osteoarthritis

Sep. 22, 2010

Palau Pharma identifies new histamine H4 receptor antagonists

Sep. 22, 2010

Preliminary phase I data on fully human anti-PNAG mAb F-598 disclosed

Sep. 22, 2010

SCH-527123 is safe and efficacious in phase II trial in COPD

Sep. 21, 2010

NFL-10808 silences presynaptic serotonin 5-HT1A receptors and has antidepressant effects in vivo

Sep. 21, 2010

Scientists reveal predictors of adverse events associated with losartan therapy for heart failure

Sep. 21, 2010

Almirall identifies new naphthyridine N-oxide as anti-inflammatory agent

Sep. 21, 2010

Ramucirumab is tolerated in patients with advanced HCC in ongoing phase II trial

Sep. 21, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...